Johnson & Johnson Completes $1 Billion Acquisition of Firefly Bio
Johnson & Johnson said in a filing that it has completed its acquisition of Firefly Bio, Inc., a biotechnology company developing a degrader antibody conjugate platform, for $1 billion in cash.





